探讨甲基强的松龙治疗急性期多发性硬化的临床效果及安全性

崔晓　刘启兵　张真

【摘要】 目的：探討甲基强的松龙治疗急性期多发性硬化的临床效果及安全性。方法：选取2013年1月-2016年6月笔者所在医院收治的80例急性期多发性硬化患者作为研究对象，随机将其分成对照组和观察组，各40例，其中对照组患者给予地塞米松静脉注射治疗，观察组患者给予甲基强的松龙静脉注射治疗。治疗结束后，比较两组患者EDSS评分、临床疗效、住院时间、总费用及不良反应发生情况。结果：观察组患者治疗5 d及出院前EDSS评分分别为（4.1±1.3）分、（2.6±1.3）分，均明显低于对照组的（5.0±1.0）分、（3.2±1.6）分，差异均有统计学意义（P<0.05）；观察组患者治疗总有效率为82.5%，明显高于对照组的62.5%，差异有统计学意义（P<0.05）；观察组患者住院时间及总费用分为为（20.6±6.6）d、（5609.2±1466.2）元，均低于对照组的（30.8±8.6）d、（9616.8±1790.2）元，差异均有统计学意义（P<0.05）；观察组患者腹部不适、向心性肥胖、失眠、痤疮和焦虑发生率均明显低于对照组患者，差异均有统计学意义（P<0.05）。结论：甲基强的松龙能够明显提高急性期多发性硬化治疗有效率，改善患者神经功能，减少住院时间，降低患者经济负担，且不良反应率低，值得临床推广应用。

【关键词】 甲基强的松龙； 多发性硬化； 疗效； 安全性

doi：10.14033/j.cnki.cfmr.2017.19.005 文献标识码 B 文章编号 1674-6805（2017）19-0011-03

The Clinical Efficacy and Safety of Methylprednisolone in the Treatment of the Patients with Acute Multiple Sclerosis/CUI Xiao，LIU Qi-bing，ZHANG Zhen.//Chinese and Foreign Medical Research，2017，15（19）：11-13

【Abstract】 Objective：To investigate the clinical efficacy and safety of Methylprednisolone in the treatment of the patients with acute multiple sclerosis.Method：During January 2013 to June 2016 in the author，s hospital，80 cases of acute multiple sclerosis patients were randomly divided into the control group and the observation group，with 40 patients in each group.The control group was treated with intravenous Dexamethasone，and the observation group was treated with intravenous injection of Methylprednisolone.After treatment，the EDSS score，clinical efficacy，length of stay，total costs，and adverse reactions of the two groups were compared.Result：The EDSS score of of the patients in the observation group treatment for 5 days and after treatment were （4.1±1.3）scores，（2.6±1.3）scores，significantly lower than （5.0±1.0）scores and （3.2±1.6）scores of the control group，the differences were statistically significant（P<0.05）.The total efficiency of the patients in the observation group was 82.5%，significantly higher than 62.5% of the control group，the difference was statistically significant （P<0.05）.The hospital stay time and the total cost of the observation group were （20.6±6.6）d and （5609.2±1466.2） yuan， lower than （30.8±8.6）d，（9616.8±1790.2）yuan of the control group，the differences were statistically significant （P<0.05）.The incidence of abdominal discomfort，central obesity，insomnia，acne and anxiety of the patients in the observation group were significantly lower than the control group，the differences were statistically significant （P<0.05）.Conclusion：Methylprednisolone can significantly improve the efficiency of the patients with acute multiple sclerosis，improve neurological function and reduce hospitalization time and reduce the economic burden of patients，and there were low adverse reactions，it was worthy of clinical application.endprint

【Key words】 Methylprednisolone； Multiple sclerosis； Efficacy； Security

First-authors address：Xuzhou Central Hospital，Xuzhou 221000，China

多发性硬化属于自身免疫疾病，常见于年轻女性人群，主要发生于视神经、脊髓和脑干[1-2]。目前，临床上以抗炎、免疫抑制和免疫调节为主，但尚无特效药物，以往多用类固醇治疗，但临床疗效较差，不良反应多[3-4]。为了探讨甲基强的松龙治疗急性期多发性硬化临床效果及安全性，在2013年1月-2016年6月笔者所在医院将80例急性期多发性硬化患者列入研究，进行对照试验，现将相关研究结果报道如下。

1 资料与方法

1.1 一般资料

选取2013年1月-2016年6月笔者所在医院收治的80例急性期多发性硬化患者，经诊断所有患者的临床症状符合多发性硬化诊断标准。随机将80例急性期多发性硬化患者分成对照组和观察组，每组40例。对照组男18例，女22例，年龄22～57岁，平均（40.2±4.3）岁；病程5个月～5年，平均（2.3±1.3）年。观察组男16例，女24例，年龄21～56岁，平均（39.4±3.7）岁；病程4个月～6年，平均（2.5±1.5）年。……